DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Pär Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody engineering at Singapore’s Nanyang Technological University. For more information visit www.dotbiopharma.com
Company Details
- Employees
- 19
- Founded
- -
- Address
- 1 Research Link, Singapore,11,singapore
- Phone
- +65 6906 0743
- in****@****rma.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- dotbiopharma.com
- Keywords
- Oncology and DotBody technology.
- HQ
- Singapore
Dotbio Questions
Dotbio's helpline number is +65 6906 0743
Dotbio's website is dotbiopharma.com
Dotbio's LinkedIn profile is https://sg.linkedin.com/company/dotbio
Dotbio has
19 employees.
View email and phone details for 19
employees at Dotbio.
Dotbio's industry is
Biotechnology Research
Dotbio's top competitors are
Bora Biologics,
Arbele,
Bora Pharmaceuticals,
Hanchorbio Inc. 漢康生技股份有限公司,
Verimmune,
Allozymes,
Uni-Bio Science Group (Hk690) 联康生物科技集团,
Xenolis Pte Ltd,
Great Bay Bio 大湾生物,
Hummingbird Bioscience.
Dotbio's support email address is info@dotbiopharma.com
Dotbio's categories are Biotechnology Research
Dotbio's founding year is 2018
